Brain, Vol. 122, No. 12, 2297-2307,
December 1999
© 1999 Oxford University Press
Review article |
Immunological profile of patients with primary progressive multiple sclerosis
Expression of adhesion molecules
Unitat de Neuroimmunologia Clínica, Servei de Neurologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain
Correspondence to:
Isabel Durán, Unitat de Neuroimmunologia Clínica, Escola d'Infermeria 5a planta, Hospital General Universitari Vall d'Hebron, Psg. Vall d'Hebron 119–129, 08035, Barcelona, Spain E-mail: iduran{at}hg.vhebron.es
Adhesion molecules are important in the trafficking of peripheral leucocytes into the central nervous system, a major event in the pathogenesis of multiple sclerosis, which is an inflammatory and demyelinating disease. The latest MRI evidence supports clinical divergence between forms of multiple sclerosis with relapses and the primary progressive form without relapses, which shows fewer and smaller inflammatory lesions. With the aim of elucidating whether different pathogenic mechanisms are involved in primary progressive multiple sclerosis, we compared membrane expression of the adhesion molecules ICAM-1 (CD54), LFA-1
(CD11a), VLA-4 [4/ß1 integrin (CD49d/CD29)], L-selectin (CD62L) and ICAM-3 (CD50) in peripheral blood and the serum-soluble forms ICAM-1, L-selectin, VCAM-1 and ICAM-3 in 89 patients (39 with the primary progressive form, 25 with the secondary progressive form and 25 with the relapsing–remitting form) and 38 healthy controls. We found a significant decrease in leucocyte surface expression of most of the adhesion molecules tested and an increase in soluble ICAM-1 and L-selectin levels in secondary progressive and relapsing–remitting multiple sclerosis compared with primary progressive multiple sclerosis, which gave results similar to those in controls. These results, which are supported by MRI evidence, show that trafficking of autoreactive leucocytes through the blood–brain barrier is crucial to the pathogenesis of secondary progressive and relapsing–remitting forms of multiple sclerosis, whereas other mechanisms leading to progressive axonal damage would account for primary progressive forms of the disease.
multiple sclerosis; primary progressive; adhesion molecules; blood–brain barrier
CPMS = `chronic progressive' multiple sclerosis; ELISA = enzyme-linked immunosorbent assay; PBL = peripheral blood lymphocytes; PPMS = primary progressive multiple sclerosis; RRMS = relapsing–remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis. For abbreviations for monoclonal antibodies, see section headed Reagents.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. E. McCandless, L. Piccio, B. M. Woerner, R. E. Schmidt, J. B. Rubin, A. H. Cross, and R. S. Klein Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of Multiple Sclerosis Am. J. Pathol., March 1, 2008; 172(3): 799 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ukkonen, X. Wu, B. Reipert, P. Dastidar, and I. Elovaara Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 701 - 707. [Abstract] [PDF]
|
|
|
|
|
|
C. Lucchinetti and W. Bruck The pathology of primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S23 - S30. [Abstract] [PDF]
|
|
|
|
|
|
R. Hohlfeld Immunologic factors in primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S16 - S22. [Abstract] [PDF]
|
|
|
|
|
|
C. Lucchinetti and W. Bruck The pathology of primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S23 - S30. [Abstract] [PDF]
|
|
|
|
 |
|
 Y Zoukos, T N Thomaides, D Kidd, M L Cuzner, and A Thompson Expression of {beta}2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 197 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E M Martinez-Caceres, C Espejo, L Brieva, I Pericot, M Tintore, I Saez-Torres, and X Montalban Expression of chemokine receptors in the different clinical forms of multiple sclerosis Multiple Sclerosis, October 1, 2002; 8(5): 390 - 395. [Abstract] [PDF]
|
|
|
|
|
|
J W Pan, P K Coyle, K Bashir, J N Whitaker, L B Krupp, and H P Hetherington Metabolic differences between multiple sclerosis subtypes measured by quantitative MR spectroscopy Multiple Sclerosis, June 1, 2002; 8(3): 200 - 206. [Abstract] [PDF]
|
|
|
|
|
|
W Bruck, C Lucchinetti, and H Lassmann The pathology of primary progressive multiple sclerosis Multiple Sclerosis, April 1, 2002; 8(2): 93 - 97. [Abstract] [PDF]
|
|
|
|
|
|
G T Ingle, V L Stevenson, D H Miller, S M Leary, M Rovaris, F Barkhof, B Brochet, V Dousset, M Filippi, X Montalban, et al. Two-year follow-up study of primary and transitional progressive multiple sclerosis Multiple Sclerosis, April 1, 2002; 8(2): 108 - 114. [Abstract] [PDF]
|
|
|
|
|
|
J Killestein, B F Den Drijver, W L Van der Graaff, B M. Uitdehaag, C H Polman, and R A. Van Lier Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease Multiple Sclerosis, June 1, 2001; 7(3): 145 - 150. [Abstract] [PDF]
|
|
|
|
|
|
I Duran, E M Martinez-Caceres, L Brieva, M Tintore, and X Montalban Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis Multiple Sclerosis, June 1, 2001; 7(3): 151 - 156. [Abstract] [PDF]
|
|